AYAL Capital Advisors Ltd Increases Holdings in Orthofix Medical Inc. $OFIX

AYAL Capital Advisors Ltd grew its holdings in shares of Orthofix Medical Inc. (NASDAQ:OFIX) by 74.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 943,203 shares of the medical device company’s stock after acquiring an additional 403,433 shares during the quarter. Orthofix Medical comprises 2.5% of AYAL Capital Advisors Ltd’s investment portfolio, making the stock its 2nd largest position. AYAL Capital Advisors Ltd owned about 2.41% of Orthofix Medical worth $10,517,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of OFIX. Engine Capital Management LP lifted its stake in Orthofix Medical by 13.6% during the second quarter. Engine Capital Management LP now owns 4,251,671 shares of the medical device company’s stock worth $47,406,000 after purchasing an additional 510,281 shares during the last quarter. Philosophy Capital Management LLC purchased a new position in shares of Orthofix Medical during the 1st quarter valued at about $6,047,000. Juniper Investment Company LLC lifted its position in Orthofix Medical by 10.3% in the 1st quarter. Juniper Investment Company LLC now owns 2,137,374 shares of the medical device company’s stock worth $34,861,000 after buying an additional 200,125 shares during the last quarter. Gabelli Funds LLC boosted its stake in Orthofix Medical by 70.8% in the second quarter. Gabelli Funds LLC now owns 257,123 shares of the medical device company’s stock worth $2,867,000 after buying an additional 106,623 shares in the last quarter. Finally, Qube Research & Technologies Ltd boosted its stake in Orthofix Medical by 179.4% in the second quarter. Qube Research & Technologies Ltd now owns 163,192 shares of the medical device company’s stock worth $1,820,000 after buying an additional 104,778 shares in the last quarter. Hedge funds and other institutional investors own 89.76% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on OFIX shares. Stifel Nicolaus assumed coverage on shares of Orthofix Medical in a report on Tuesday, October 28th. They issued a “buy” rating and a $22.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Orthofix Medical in a research note on Wednesday, October 8th. Finally, Barrington Research raised their price objective on Orthofix Medical from $17.00 to $18.00 and gave the company an “outperform” rating in a research note on Wednesday, November 5th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $21.50.

Orthofix Medical Trading Down 1.4%

Shares of OFIX opened at $15.49 on Friday. The stock has a market capitalization of $613.40 million, a P/E ratio of -5.11 and a beta of 0.82. Orthofix Medical Inc. has a twelve month low of $10.24 and a twelve month high of $20.48. The company has a quick ratio of 1.38, a current ratio of 2.47 and a debt-to-equity ratio of 0.39. The firm has a fifty day simple moving average of $15.31 and a two-hundred day simple moving average of $13.54.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.